Oral News and Research

RSS

Research roundup: Home health nurses' workloads; readmissions at the VA; SHOP choices

In anticipation of next year's premium announcements and given some information already made public, concerns have surfaced about the potential for double-digit percent increases in nongroup and small-group health insurance premiums. This analysis shows that, although average annual increases in small-group premiums over the past 13 years averaged roughly 5.5 percent, double-digit average premium increases are common for states and large metropolitan areas.

22 Sep 2014

SLU pediatric researcher to study efficacy of new hepatitis C drug treatment in children

After the success of a new drug treatment in adults with hepatitis C infection, a Saint Louis University pediatric researcher is testing the safety and efficacy of the medications in children.

21 Sep 2014

Fast decline in insulin sensitivity seen in pre-diabetic South Asians

People of south Asian descent who have Type 2 diabetes show a more rapid decline in fasting glucose levels than White individuals even before they develop the disease, new findings from the Whitehall II study suggest.

18 Sep 2014

First data from phase 3 study of investigational once-weekly DPP-4 inhibitor for type 2 diabetes presented by MSD

MSD, known as Merck & Co., Inc. (NYSE: MRK) in the United States and Canada, today announced the presentation of the first data from the Phase 3 clinical development programme for omarigliptin, MSD’s investigational treatment for type 2 diabetes.

18 Sep 2014

S-1 plus radiotherapy shows promise in elderly NSCLC patients

Concurrent administration of S-1 chemotherapy and radiotherapy has a favourable impact on survival in elderly patients with locally advanced non-small-cell lung cancer, a phase II trial has found.

17 Sep 2014

High impact health interventions reduce maternal and child mortality in poor countries

New studies have uncovered the specific interventions and advances that have led to the success with these at-risk populations in the poorest countries.

17 Sep 2014

Janssen announces availability of PREZCOBIX for Canadians living with HIV

Janssen Inc. announced today that PREZCOBIX (darunavir/cobicistat), a once-daily, oral medication for the treatment of HIV infection in combination with other antiretroviral agents, is now available in Canada. It is the first HIV treatment option available to patients that provides boosted darunavir in a single tablet.

17 Sep 2014

New guidance can help physicians determine best oral blood thinners for patients

Physicians around the world now have guidance that can help them determine the best oral blood thinners to use for their patients suffering from blood clots in their veins, thanks to a patient of The Ottawa Hospital who asked his physician a question he couldn't answer.

17 Sep 2014

MOVANTIK tablets get FDA approval for treatment of OIC in patients with chronic, non-cancer pain

Nektar Therapeutics reported today that partner AstraZeneca today announced that the US Food and Drug Administration (FDA) approved MOVANTIK (naloxegol) tablets as the first once-daily oral peripherally-acting mu-opioid receptor antagonist (PAMORA) medication for the treatment of opioid-induced constipation (OIC), in adult patients with chronic, non-cancer pain.

16 Sep 2014

Lilly, AstraZeneca partner to co-develop and commercialize potential Alzheimer's disease treatment

Eli Lilly and Company and AstraZeneca today announced an agreement to co-develop and commercialize AZD3293, an oral beta secretase cleaving enzyme (BACE) inhibitor currently in development as a potential treatment for Alzheimer's disease.

16 Sep 2014

Bayer, Orion begin patient enrollment in ODM-201 Phase III trial for castration-resistant prostate cancer

Bayer HealthCare and Orion Corporation, a pharmaceutical company based in Espoo, Finland, have begun to enroll patients in a Phase III trial with ODM-201, an investigational oral androgen receptor inhibitor in clinical development.

16 Sep 2014

Health clinics getting new $295 million for primary care through health law

The money will go to expanding primary care services, as well as helping health centers stay open longer and provide expanded services not always available at the clinics across the United States.

16 Sep 2014

Gilead to boost price of new hepatitis c drug

Gilead Sciences says its next generation drug to combat hepatitis C, slated to launch next month, will be more expensive than $1,000-a-pill Sovaldi, in part because the new treatment will be shorter and simpler. Gilead also struck a deal with Indian generic drugmakers to sell lower-cost versions of Sovaldi in poor countries.

From Baxter International Inc. 16 Sep 2014

GHIT Fund announces new grants to tackle malaria, chagas disease and dengue

The Global Health Innovative Technology Fund, a new public health partnership that is bringing Japanese know-how and investment to the global fight against infectious diseases, today announced seven grant investments totaling US$15.3 million to speed the development of promising drugs and vaccines to battle three insect-borne diseases-malaria, dengue and Chagas disease.

16 Sep 2014

Amgen announces phase 3 ivabradine data for treatment of chronic HF

Amgen (NASDAQ: AMGN) today announced data from the Phase 3 SHIFT (Systolic Heart failure treatment with the If inhibitor ivabradine Trial) study evaluating ivabradine in patients with chronic heart failure (HF) were presented at the 18th Annual Scientific Meeting of the Heart Failure Society of America (HFSA) in Las Vegas.

15 Sep 2014

Instrumentation Laboratory announces launch of HemosIL Direct Thrombin Inhibitor Assay in Europe

Instrumentation Laboratory today announced the commercialization in Europe of their HemosIL Direct Thrombin Inhibitor (DTI) Assay. When used in conjunction with HemosIL Dabigatran Calibrators and Controls, this test offers an automated solution for the measurement of dabigatran, a direct oral anticoagulant (DOAC).

15 Sep 2014

New antiseptic agent holds promise for treatment of periodontitis

The study, published in the journal Science and Technology of Advanced Materials, by Shinichi Arakawa and colleagues at Tokyo Medical and Dental University and Japan's National Institute of Advanced Industrial Science and Technology, evaluated the bactericidal activities of ozone nano-bubble water - also known as NBW3 - against the two main bacterial agents that cause periodontitis as well as its toxicity to human oral tissue cells.

15 Sep 2014

GILZ protein key to preventing bone loss, researchers report

A small protein named GILZ appears to protect against the bone loss that often accompanies arthritis and its treatment, researchers report.

15 Sep 2014

People who take antidepressants are twice as likely to have dental implants fail

A team from McGill University has discovered that people who take the most common antidepressants (such as Celexa, Paxil, Lexapro, Prozac, and Zoloft, the Selective Serotonin Reuptake Inhibitors or SSRIs) are twice as likely to have dental implants fail as those who are not taking SSRIs.

12 Sep 2014

FDA approves Contrave extended-release tablets for chronic weight management

Takeda Pharmaceuticals U.S.A., Inc. and Orexigen® Therapeutics, Inc. jointly announced today that the U.S. Food and Drug Administration has approved Contrave® extended-release tablets as an adjunct to a reduced-calorie diet and increased physical activity for chronic weight management in adults with an initial body mass index of 30 kg/m2 or greater (obese), or 27 kg/m2 or greater (overweight) in the presence of at least one weight-related comorbid condition.

11 Sep 2014

Oral News and Research

Research roundup: Home health nurses' workloads; readmissions at the VA; SHOP choices

SLU pediatric researcher to study efficacy of new hepatitis C drug treatment in children

Fast decline in insulin sensitivity seen in pre-diabetic South Asians

First data from phase 3 study of investigational once-weekly DPP-4 inhibitor for type 2 diabetes presented by MSD

S-1 plus radiotherapy shows promise in elderly NSCLC patients

High impact health interventions reduce maternal and child mortality in poor countries

Janssen announces availability of PREZCOBIX for Canadians living with HIV

New guidance can help physicians determine best oral blood thinners for patients

MOVANTIK tablets get FDA approval for treatment of OIC in patients with chronic, non-cancer pain

Lilly, AstraZeneca partner to co-develop and commercialize potential Alzheimer's disease treatment

Bayer, Orion begin patient enrollment in ODM-201 Phase III trial for castration-resistant prostate cancer

Health clinics getting new $295 million for primary care through health law

Gilead to boost price of new hepatitis c drug

GHIT Fund announces new grants to tackle malaria, chagas disease and dengue

Amgen announces phase 3 ivabradine data for treatment of chronic HF

Instrumentation Laboratory announces launch of HemosIL Direct Thrombin Inhibitor Assay in Europe

New antiseptic agent holds promise for treatment of periodontitis

GILZ protein key to preventing bone loss, researchers report

People who take antidepressants are twice as likely to have dental implants fail

FDA approves Contrave extended-release tablets for chronic weight management

Expanding access to NMR with the Fourier 80 Duo

Advancing Intracellular Delivery with LumiPore®

How ELRIG Is Helping Mid-Career Scientists Navigate Leadership, Career Change and Redundancy

Latest News